Live Feeds
● LIVE Updated 7h ago Β· 17 sources tracked

Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development

Pfizer has signed a strategic funding agreement with Blackstone Life Sciences to advance its monthly GLP-1 obesity drug berobenatide through Phase 3 studies. Blackstone will provide up to $1.5 billion through 2028, according to PharmaExec. Pfizer acquired the asset by winning a bidding war for Metsera, the drug's previous owner. The deal supports a sprawling Phase 3 program as Pfizer seeks to compete in the crowded weight-loss drug market.

πŸŽ™οΈ

Listen to Live Briefing

Real-time synthesized voice briefing Β· Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (17)
⚑ Key Developments & Real-Time Context
Text size:
  • βœ“ Pfizer and Blackstone Life Sciences signed a co-funding deal in which Blackstone will provide up to $1.5 billion through 2028 to advance berobenatide.
  • βœ“ The funding supports a Phase 3 program for a monthly GLP-1 obesity shot Pfizer acquired by winning a bidding war for Metsera.
πŸ›‘οΈ Source Corroboration: 17 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

Pfizer and Blackstone have announced a co-funding agreement for berobenatide, replacing earlier speculation that Pfizer would fund the obesity program entirely from its own balance sheet.

Live updates

  1. Pfizer and Blackstone agree up to $1.5 billion co-funding deal for obesity drug berobenatide

    Pfizer has signed a strategic funding agreement with Blackstone Life Sciences to advance its monthly GLP-1 obesity drug berobenatide through Phase 3 studies. Blackstone will provide up to $1.5 billion through 2028, according to PharmaExec. Pfizer acquired the asset by winning a bidding war for Metsera, the drug's previous owner. The deal supports a sprawling Phase 3 program as Pfizer seeks to compete in the crowded weight-loss drug market.

    Why it matters

    The agreement shifts much of the financial risk of late-stage obesity drug development onto Blackstone while Pfizer retains a path to commercialization. Berobenatide is a once-monthly GLP-1 shot positioned as Pfizer's answer to Novo Nordisk's Wegovy and Eli Lilly's Zepbound. The Metsera acquisition gave Pfizer control of the candidate after a competitive auction. What remains unresolved is how the economics are split between the two parties and when Phase 3 data will read out.

    What is confirmed

    • Pfizer and Blackstone Life Sciences signed a co-funding deal in which Blackstone will provide up to $1.5 billion through 2028 to advance berobenatide.
    • The funding supports a Phase 3 program for a monthly GLP-1 obesity shot Pfizer acquired by winning a bidding war for Metsera.

    Still unconfirmed

    • Pfizer will retain full commercialization rights to berobenatide after Blackstone's funding commitment ends.
    • Blackstone's investment will secure Pfizer a top-three position in the global obesity drug market by 2029.

    What to watch next

    • Phase 3 trial initiation and enrollment targets for berobenatide
    • Disclosure of revenue-sharing and milestone terms between Pfizer and Blackstone
    • Top-line readout timing for the monthly GLP-1 obesity shot
    Sources used for this update (17)
    1. www.marketscreener.com β€” Global Stocks Fall on Higher Oil Prices, AI Pullback | MarketScreener
    2. www.biospace.com β€” GSK restructure will hit home, impacting 'limited' UK roles
    3. www.wallstreetzen.com β€” Sandisk Stock Price Today (NASDAQ: SNDK) Quote, Market Cap, Chart
    4. WSJ β€” Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
    5. Reuters β€” Pfizer secures up to $1.5 billion from Blackstone for obesity drug development
    6. Yahoo Finance β€” Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program
    7. Bloomberg.com β€” Blackstone Puts Up $1.5 Billion for Pfizer Obesity Drug Studies
    8. Stocks Down Under β€” Pfizer (NYSE:PFE) Is Getting $1.5bn From Blackstone To Fund Its GLP-1 Ambitions
    9. Fierce Biotech β€” Pfizer taps Blackstone for up to $1.5B to pave path to GLP-1's obesity launch
    10. Quartz β€” Pfizer is tapping Blackstone for up to $1.5 billion to fund its weight-loss drug
    11. Barron's β€” Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug
    12. BioPharma Dive β€” Blackstone bets $1.5B on Pfizer’s obesity drug
    confidence 90%
πŸ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective Β· Real-time aggregated sentiment from the Live Feeds community